•  SciRhom will use the upsized and oversubscribed Series A financing to drive its lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy
  • Financing led by top-tier investor syndicate including Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors, among them High-Tech Gründerfonds and PhiFund Ventures 

 Andera Partners, a leading European private equity player, announced today that it is co-leading a € 63 million ($ 70 million) Series A financing for SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies. The financing round was led by an investor syndicate which, in addition to Andera, includes new investors Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors, among them High-Tech Gründerfonds (HTGF) and PhiFund Ventures. The new funds will be used to accelerate and broaden the impact of the company’s innovative therapeutic strategy in autoimmune disorders. The first clinical study evaluating SR-878, a highly specific monoclonal antibody for iRhom2, is expected to start dosing in the second half of 2024. 

SciRhom was founded with the mission to provide a new treatment paradigm for autoimmune diseases and potentially other indications by selectively addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The SciRhom team collaborated closely with co-founders Prof. Carl Blobel and the Hospital for Special Surgery (HSS), the world’s leading academic medical center specialized in Rheumatology and musculoskeletal health, where Prof. Blobel serves as Director of the Arthritis and Tissue Degeneration Program. He has made seminal contributions to the understanding of how iRhom2 controls the activity of TACE/ADAM17 in inflammation and autoimmune diseases. SciRhom designed its most advanced development candidate SR-878 to simultaneously block several pro-inflammatory and disease-driving pathways, including TNF-alpha, IL-6R, and EGFR signaling, while preserving other vital functions dependent on TACE/ADAM17. This unique ability to attack multiple cytokines and to potentially promote immune tolerance through restoring beneficial TNFR2 signaling and regulatory T-cell expansion is expected to have a transformative effect in patients across a wide range of autoimmune diseases. Moreover, the selective targeting of iRhom2 is expected to have a favorable safety profile. 

Since its foundation, SciRhom has applied rigorous science to establish a leading position in iRhom2-targeting biopharmaceuticals including a comprehensive IND/CTA-enabling data and CMC package and strong patent protection. Now is the time to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy towards clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments,” commented Dr. Jens Ruhe, co-founder, Managing Director and COO of SciRhom. 

Based on positive preclinical data sets generated in vitro and in established animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), SciRhom has advanced its first program to a Phase 1-ready stage. As announced on June 12th, 2024, the first CTA approval was achieved paving the way for initiating a first clinical study in Austria in the second half of 2024. The study aims to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in the second part of the study. 

Dr. Jan Poth, Managing Director and CEO of SciRhom, added: “We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. We look forward to collaborating with our new as well as existing partners and board members to bring a differentiated therapeutic option to patients and address the unmet medical need for much more effective and safe treatments for autoimmune disorders.” 

In conjunction with this investment, Dr. Olivier Litzka from Andera Partners, Dr. Peter Neubeck from Kurma Partners, Dr. Georgina Askeland from Hadean Ventures, Dr. Fei Tian from MIG Capital and Dr. Varun Gupta from Wellington Partners will join SciRhom’s Board of Directors. 

Olivier Litzka, PhD, Partner at Andera Partners in Munich, stated: “Building on our investments in promising biotech companies in the region such as Tubulis, Tricares, t-knife and Ariceum, the financing of SciRhom is our third life sciences investment in Germany within three years out of our BioDiscovery 6 fund. We are excited to further strengthen our footprint in the DACH region by partnering with the experienced and dedicated team at SciRhom and such an esteemed syndicate of investors. SciRhom’s pioneering approach to targeting iRhom2, a key driver of inflammation, has transformative potential for patients with autoimmunne diseases and we look forward to supporting the company as it starts clinical development of its novel iRhom2-targeting antibody.” 

Share on :

More news